Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes

Journal of Clinical Pharmacology

Volumn 43, Issue 11, 2003, Pages 1244-1256

  Skrumsager, Birte K ^a   Nielsen, K K ^a   Muller M ^b   Pabst, G ^b   Drake, P G ^a   Edsberg, B ^a  

^a NOVO NORDISK A S   (Denmark)

^b AAI Deutschland GmbH and Co KG   (Germany)

Author keywords

Diabetic dyslipidemia; Pharmacodynamics; Pharmacokinetics; Ragaglitazar; Tolerability; Type 2 diabetes

Indexed keywords

C PEPTIDE; CELL RECEPTOR; FATTY ACID; FRUCTOSAMINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXAZINE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PHENYLPROPIONIC ACID DERIVATIVE; PLACEBO; RAGAGLITAZAR; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OXAZINES; PHENYLPROPIONATES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0142135388     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003257230     Document Type: Article

References (34)

1. Dostou J, Gerich J: Pathogenesis of type 2 diabetes mellitus. Exp Clin Endocrinol Diabet 2001;109:S149-S156.
2. Kaplan F, Al Majali K, Betteridge DJ: PPARS, insulin resistance and type 2 diabetes. J Cardiovasc Risk 2001;8(4):211-217.
3. Betteridge DJ: Dyslipidaemia and diabetes. Pract Diabetes Int 2001;18(6):201-207.
4. Taskinen M: Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diabetes 2001;109(Suppl. 2):S180-S188.
5. Moller DE, Greene DA: Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes. Adv Protein Chem 2001;56:181-212.
6. UK-Prospective DSG: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-853.
7. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol-lowering with simvastatin improves prognosis of diabetic-patients with coronary heart-disease: a sub-group analysis of the Scandinavian Simvastatin Survival Study. Diabetes Care 1997;20:1048-1048.
8. Steiner G, Hamsten A, Hosking J, Stewart D, McLaughlin P, Gladstone P, et al: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357(9260):905-910.
9. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, et al: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998;98(23):2513-2519.
10. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276(23):1886-1892.
11. Lohray BB, Lohray VB, Bajji AC, Kalchar S, Poondra RR, Padakanti S, et al: (-)3-[4-[2-(Phenoxazin-10-yl)ethoxylphenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J Med Chem 2001;44(16):2675-2678.
12. Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wassermann K, et al: Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARα/γ agonists with hypolipidemic and antidiabetic activity. J Med Chem 2002;45:789-804.
13. Vamecq J, Latruffe N: Medical significance of peroxisome proliferator-activated receptors. Lancet 1999;354(9173):141-148.
14. Bailey CJ: Potential new treatments for type 2 diabetes. Trends Pharmacol Sci 2000;21(7):259-265.
15. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 2000;405(6785):421-424.
16. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, et al: Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278(3):704-711.
17. World Medical Association: Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277(11):925-926.
18. Andersen MP, Nielsen KK: Determination of ragaglitazar, a novel dual acting peroxisome proliferator-activated receptor (PPAR) α and γ agonist, in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B 2003;788(1):45-55.
19. Wulff EM, Jeppesen L, Bury PS, Mogensen JP, Fleckner J, Andersen AT, et al: Characterisation of future generation insulin sensitizers in vitro and in vivo. Diabetes 2001;50(Suppl. 2):A524.
20. Brand CL, Sturis J, Godfredsen CF, Fleckner J, Fledelius C, Hansen BF, et al: Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am J Physiol Endocrinol Metabol 2003;284:E841-E854.
21. Ye J, Iglesias MA, Watson DG, Ellis B, Wood L, Jensen PB, et al: PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 2003;284:E531-E540.
22. Skrumsager BK, Pedersen PC, Nielsen KK, Mueller M: Ragaglitazar: no pharmacokinetic differences between young and elderly, male and female subjects, fasted and non-fasted state including impact of hepatic recycling on the plasma elimination half-life. Diabetologia 2002;45(Suppl. 2):A232.
23. Skrumsager BK, Nielsen KK, Reinhardt R, Pedersen PC: NNC 61-0029 ((-)DRF2725): the single dose pharmacokinetics of a novel dual acting PPARα and PPARγ agonist in Caucasian and Japanese healthy subjects. Diabetes 2001;50(Suppl. 2):A445.
24. McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, et al: Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. Br Med J 1994;308(6940):1323-1328.
25. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23(11):1605-1611.
26. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86(1):280-288.
27. Steiner G, Hamsten A, Hosking J, Steward D, McLaughlin P, Gladstone P, et al: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357(9260):905-910.
28. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285(12):1585-1591.
29. Buse JB: Pioglitazone in the treatment of type 2 diabetes mellitus: U.S. clinical experience. Exp Clin Endocrinol Diabetes 2000;108(Suppl. 2):S250-S255.
30. Hanefeld M, Belcher G: Safety profile of pioglitazone. Int J Clin Pract 2001;55(Suppl. 121):27-31.
31. Lebovitz HE, Banerji MA: Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001;56:265-294.
32. Gotzkowsky SK, Kashuba ADM, Hall W, Kulaway RW, Beck DJ, Rocci ML, et al: Poor correlation between 24 hr urinary 6βhydroxycortisol: cortisol molar ratios (CMR) and plasma midazolam clearance (MDZ CL) as measures of hepatic CYP3A activity. Clin Pharm Ther 1999;65(2):167.
33. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4(4):171-184.
34. Koup JR, Anderson GD, Loi CM: Effect of troglitazone on urinary excretion of 6β-hydroxycortisol. J Clin Pharmacol 1998;38(9):815-818.